References
- Kaltsonoudis E, Pelechas E, Voulgari PV, et al. Unmet needs in the treatment of rheumatoid arthritis. An observational study and a real-life experience from a single university center. Semin Arthritis Rheum. 2018 Jun 22. pii: S0049-0172(18)30188–4. DOI:10.1016/j.semarthrit.2018.06.003
- Kos IA, Azevedo VF, Neto DE, et al. The biosimilars journey: current status and ongoing challenges. Drugs Context. 2018 Oct 1;7:212543. eCollection 2018. Review.
- Schellekens H, Lietzan E, Faccin F, et al. Biosimilar monoclonal antibodies: the scientific basis for extrapolation. Expert Opin Biol Ther. 2015;15(11):1633–1646.
- Gulacsi L, Brodszky V, Baji P, et al. Biosimilars for the management of rheumatoid arthritis: economic considerations. Expert Rev Clin Immunol. 2015;11:43–52.
- Dorner T, Strand V, Cornes P, et al. The changing landscape of biosimilars in rheumatology. Ann Rheum Dis. 2016;75:974–982.
- GaBI Online – Generics and Biosimilars Initiative. Biosimilar etanercept offered at 47% discount in Norway [www.gabiolinile.net]. Mol: Pro Pharma Communications International; [cited 2018 Sep 12]. Available from: http://wwwgabionline.net/Biosimilars/General/Biosimilar-etanercept-offered-at-47-discount-in-Norway
- Pelechas E, Voulgari PV, Drosos AA. ABP501 for the treatment of rheumatoid arthritis. Expert Opin Biol Ther. 2018;18(3):317–322.
- European Medicines Agency. Enbrel. Annex I. Summary of product characteristics; [cited 2018 Sep 12]. Available from: http://www.ema.europa.eu/docs/en_GB/document/library/EPAR_-_Product_Information/human/000262/WC500027361.pdf
- European Medicines Agency. Benepali. Annex I. Summary of product characteristics; [cited 2018 Sep 12]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/004007/WC500200378.pdf
- Barbour KE, Helmick CG, Theis KA, et al. Prevalence of doctor-diagnosed arthritis and arthritis-attributable activity limitation – United States, 2010–2012. MMWR. 2013;62(44):869–873.
- Centers for Disease Control and Prevention. National and state medical expenditures and lost earnings attributable to arthritis and other rheumatic conditions – United States, 2003. MMWR. 2007;56(1):4–7.
- Kobelt G, Kasteng F Access to innovative treatments in rheumatoid arthritis in Europe. European Federation of Pharmaceutical Industry Association (EFPIA); 2009 [cited 2018 Oct 2]. Available from: http://www.comparatorreports.se/Access%20to%20RA%20Treatments%20October%202009.pdf.
- Westhovens R, Annemans L. Costs of drugs for treatment of rheumatic diseases. RMD Open. 2016;2:e000259.
- Lee YJ, Shin D, Kim Y, et al. A randomized phase I pharmacokinetic study comparing SB-4 and etanercept reference product (Enbrel) in health subjects. Br J Clin Pharmacol. 2016;82:64–73.
- Emery P, Vencovsky J, Sylwestrzak A, et al. A phase III randomised, double-blind, parallel-group study comparing SB-4 with etanercept reference product in patients with active rheumatoid arthritis despite methotrexate therapy. Ann Rheum Dis. 2017;76:51–57.
- Cho IH, Lee N, Song D, et al. Evaluation of the structural, physicochemical, and biological characteristics of SB4, a biosimilar of etanercept. MAbs. 2016;8(6):1136–1155.
- European Medicines Agency. Benepali – etanercept; [cited 2018 Oct 3]. Available from: https://www.ema.europa.ej/documents/product-information/benepali-epar-product-information_en.pdf
- European Medicines Agency. Guideline on similar biological medicinal products; [cited 2018 Oct 3]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2014/10/WC500176768.pdf
- US Department of Health and Human Services. Food and drug consideration in demonstrating biosimilarity of a therapeutic protein product to a reference product. Guidance for industry; [cited 2018 Oct 3]. Available from: http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm291134.pdf
- Emery P, Vencovsky J, Sylwestrwak A, et al. 52-week results of the phase 3 randomized study comparing SB-4 with reference etanercept in patients with active rheumatoid arthritis. Rheumatology (Oxford). 2017;56(12):2093–2101.
- Girolomoni G, Feldman SR, Emery P. Comparison of injection-site reactions between the etanercept biosimilar SB-4 and the reference etanercept in patients with rheumatoid arthritis from a phase III study. Br J Dermatol. 2018;178:215–216.
- Scheinberg M, Azevedo V. Difference between Enbrel and Benepali treatment groups in “hepatobiliary disorders”. Ann Rheum Dis. 2016;75:e64.
- Emery P, Vencovsky J, Ghil J, et al. Difference between SB-4 and reference etanercept in the hepatobiliary disorders not considered to be caused by SB-4: response to letter by Scheinberg and Azevedo. Ann Rheum Dis. 2016;75:e65.
- European Medicines Agency/CHMP/819219/2015Committee for Medicinal Products for Human Use (CHMP) Assessment report. Benepali international non-proprietary name: etanercept. (Procedure No. EMEA/H/C/004007/0000). [cited 2018 Dec 12]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/004007/WC500200380.pdf
- Graham KF, McEntegart A. Pneumocystis jiroveci pneumonia in a patient taking Benepali for rheumatoid arthritis. BMJ Case Rep. 2018. DOI:10.1136/bcr-2018-224764
- Spinelli FR, Valesini G. Immunogenicity of anti-tumour necrosis factor drugs in rheumatic diseases. Clin Exp Rheumatol. 2013;31:954–963.
- Danese S, Fiorino G, Reinisch W. Review article: causative factors and the clinical management of patients with Crohn’s disease who lose response to anti-TNF-α therapy. Aliment Pharmacol Ther. 2011;34:1–10.
- Aarden L, Ruuls SR, Wolbink G. Immunogenicity of anti-tumor necrosis factor antibodies-toward improved methods of anti-antibody measurement. Curr Opin Immunol. 2008;20:431–435.
- Van Schouwenburg PA, van de Stadt LA, de Jong RN, et al. Adalimumab elicits a restricted anti-idiotypic antibody response in autoimmune patients resulting in functional neutralisation. Ann Rheum Dis. 2013;72:104–109.
- Ungar B, Chowers Y, Yavzori M, et al. The temporal evolution of anti-drug antibodies in patients with inflammatory bowel disease treated with infliximab. Gut. 2014;63:1258–1264.
- Steenholdt C, Al-Khalaf M, Brynskov J, et al. Clinical implications of variations in anti-infliximab antibody levels in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2012;18:2209–2217.
- Casteele NV, Gils A, Singh S, et al. Antibody response to infliximab and its impact on pharmacokinetics can be transient. Am J Gastroenterol. 2013;108:962–971.
- Meacci F, Manfredi M, Infantino M, et al. Anti-etanercept and anti-SB-4 antibodies detection: impact of the assay method. Ann Rheum Dis. 2016 Apr 29. Published Online First. DOI:10.1136/annrheumdis-2016-209665
- Emery P, Vencovsky J, Kang JW, et al. Confirmation on the immunogenicity assay used in the SB-4 phase III study: response to the comments by Meacci et al. Ann Rheum Dis. 2016 May 17. Published Online First. DOI:10.1136/annrheumdis-2016-209696
- Shah CA. Lower anti-drug antibodies with etanercept biosimilar: can ctrough explain the differences? Ann Rheum Dis. 2016;75:e60.
- European Medicines Agency (EMA). Biosimilars in EU. Information guide for healthcare professionals. London: EMA; 2017 [cited 2018 Dec 12]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Leaflet/2017/05/WC500226648.pdf
- Kay J, Schoels MM, Dorner T, et al. Consensus-based recommendations for the use of biosimilars to treat rheumatological diseases. Ann Rheum Dis. 2018;77(2):165–174.
- Fleischmann R. Editorial: the American college of rheumatology white paper on biosimilars: it isn’t all white-there is some gray and black. Arthritis Rheumatol. 2018;70(3):323–325.
- Cantini F, Benucci M. Switching from the bio-originators to biosimilar: is it premature to recommend this procedure? Ann Rheum Dis. 2017 Dec 29. Epub.
- Cantini F, Benucci M. Focus on biosimilar etanercept – bioequivalence and interchangeability. Biologics. 2018;12:87–95.
- Tweehuysen L, Huiskes VJB, van den Bemt BJF, et al. Open-label non-mandatory transitioning from origintaor etanercept to biosimilar sb4; six-month results from a controlled cohort study. Arthritis Rheumatol. 2018;70(9):1408–1418. DOI:10.1002/art.40516
- Glintborg B, Sorensen I, Loft A, et al. FRI0190 clinical outcomes from a nationwide non-medical switch from originator to biosimilar etanercept in patients with inflammatory arthritis after 5 months follow-up. Results from the DANBIO registry. Ann Rheum Dis. 2017;76(Suppl 2):553–554.
- Alten R, Jones H, Curiale C, et al. SAT0201 real world evidence on switching between etanercept and its biosimilar in rheumatic diseases. Ann Rheum Dis. 2018;77(Suppl 2):961.
- Thakur K, Biberger A, Handrich A, et al. Patient perceptions and preferences of two etanercept autoinjectors for rheumatoid arthritis: findings from a patient survey in Europe. Rheumatol Ther. 2016;3:245–256.
- Egeth M, Soosaar J, Nash P, et al. Patient and healthcare professionals preference for Brenzys vs. Enbrel autoinjector for rheumatoid arthritis: a randomized crossover simulated-use study. Adv Ther. 2017;34:1157–1172.